36 research outputs found

    Rate of hospitalization due to infectious disease and rate of death with infection among biological and adoptive siblings, in <i>predisposed</i> siblings compared to <i>non-predisposed</i>.

    No full text
    <p>Analyses are stratified by sex of adoptee and sibling, and by birth year group of adoptee and sibling. Siblings of the same adoptee are analysed in one model allowing for correlation between observations.</p>1<p>Siblings to an adoptee hospitalized with infection or with infection as a cause of death.</p>2<p>Siblings to an adoptee hospitalized with infection.</p>3<p>Siblings to an adoptee with infection as a cause of death.</p>4<p>Assuming additive genetic effect on the log hazard scale.</p>5<p>Assuming additive genetic effect is inappropriate.</p

    Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse – a population-based study of 16,253 incident patients with schizophrenia

    No full text
    <p><b>Objective</b>: Clinical trials have indicated antipsychotic effects of non-steroidal anti-inflammatory drugs (NSAIDs) among incident patients with schizophrenia. We aimed to study, in a population-based setting, whether concomitant use of NSAIDs or paracetamol, changed 2-year relapse risk for schizophrenia.</p> <p><b>Methods</b>: We identified all incident patients with schizophrenia in Denmark diagnosed 1996–2012 initiating antipsychotic treatment within the year after diagnosis. We calculated concomitant treatment intervals for antipsychotic and NSAID or paracetamol use. Hazard rate ratios (HRR) were estimated using Cox regression adjusted for important covariates.</p> <p><b>Main outcome measures</b>: 2-year relapse, i.e. (re)-hospitalizations with schizophrenia.</p> <p><b>Results</b>: Among 16,235 incident patients with schizophrenia using antipsychotics, 1480 (9.1%) used NSAIDs and 767 (4.7%) paracetamol. Concomitant use of NSAIDs was associated with an increased risk of schizophrenia relapse (HRR = 1.21; 95%-CI = 1.11-1.31), particularly associated with acetylsalicylic acid and diclofenac. Concomitant use of paracetamol was not associated with schizophrenia relapse (HRR = 0.97; 95%-CI = 0.87-1.08). Subgroup analyses showed that individuals with somatic comorbidity and NSAID use had an increased relapse-risk, except for individuals with a prior hospital diagnosis for musculoskeletal disease and NSAID use who had a decreased relapse-risk (HRR = 0.82; 95%-CI = 0.71-0.94).</p> <p><b>Conclusions</b>: The increased relapse risk associated with concomitant NSAID use among incident patients with schizophrenia may indicate a potential impact of underlying somatic comorbidity.</p

    Standardized Mortality Ratios in the period 1970 to 2006 of the 12,729 Danish adoptees with the general Danish population as reference.

    No full text
    <p>Numbers of deaths among the adoptees and gender specific SMR of all death causes combined and for deaths with infections, vascular causes, cancer, alcohol-related deaths and suicides.</p
    corecore